Table 4.

Laboratory parameters over time before and after switching from tenofovir DF to abacavir, stratified by atazanavir versus non-atazanavir regimens

	Atazanavir (n=141)				Non-atazanavir (n=145)
Parameter (reference range)	Baseline	At 3 months	At 6 months	At 12 months	Baseline	At 3 months	At 6 months	At 12 months
CD4, cells/mm3 (410–1130)	500 (365–650)	510 (360–690)	550 (410–740)	560 (430–730)	490 (340–660)	490 (320–720)	550 (366–700)	530 (370–750)
pVL<50 copies/mL	95.0%	92.2%	92.8%	93.2%	96.6%	96.1%	93.7%	95.6%
Creatinine, µmol/L (45–110)	94 (79–114)	90 (81–101)	89 (75–101)	88 (75–99)	93 (81–108)	87 (77–99)	85 (77–98)	86 (78–98)
eGFR, mL/min (>59)	74 (60–87)	77 (68–88)	81 (70–91)	80 (68–88)	75 (59–89)	78 (66–95)	81 (69–90)	80 (69–91)
Phosphorus, mmol/L (0.8–1.5)	0.90 (0.80–1.06)	0.94 (0.81–1.10)	0.95 (0.83–1.08)	0.95 (0.80–1.05)*	0.92 (0.68–1.01)	0.93 (0.81–1.04)	0.94 (0.81–1.02)	0.88 (0.75–0.96)*
UACR, mg/mmol (<2.0)	2.50 (0.80–8.40)	1.30 (0.70–5.30)	1.30 (0.70–4.60)	1.30 (0.70–4.00)	2.85 (0.80–13.85)	4.0 (1.0–12.3)	1.40 (0.80–4.30)	1.80 (0.90–5.30)
Total cholesterol, mmol/L (<5.20)	4.29 (3.86–5.17)	5.23 (4.62–5.84)	5.18 (4.39–5.73)	5.10 (4.60–5.70)	4.36 (3.93–5.10)	5.25 (4.29–5.72)	5.05 (4.26–5.54)	4.82 (4.10–5.49)
LDL, mmol/L (<3.4)	2.52 (2.13–3.16)	2.65 (2.25–3.21)	2.70 (2.31–3.42)	2.74 (2.23–3.26)	2.55 (2.06–3.26)	2.60 (2.21–3.80)	2.69 (2.09–3.39)	2.63 (2.02–3.04)
HDL, mmol/L (>0.90)	1.19 (1.04–1.34)	1.25 (1.08–1.52)	1.20 (1.05–1.52)	1.21 (1.10–1.48)	1.08 (0.96–1.40)	1.17 (1.02–1.41)	1.21 (1.02–1.59)	1.24 (1.08–1.54)
Triglycerides, mmol/L (<1.50)	1.47 (1.04–2.17)	2.26 (1.58–3.05)	1.85 (1.26–2.66)	2.21 (1.47–3.08)*	1.29 (0.90–2.00)	1.71 (1.46–2.80)	1.40 (1.14–2.57)	1.70 (1.14–2.32)*

Data shown as median (interquartile range) except plasma viral load (pVL), shown as percentage of study population in each group.

^*p<0.05 for comparison between groups.